Mirogabalin: could it be the next generation gabapentin or pregabalin?

키워드

참고문헌 (57)

1. Dolphin AC, "The α2δ subunits of voltage-gated calcium channels", Biochim Biophys Acta, 1828, pp.1541~1549 (2013)
2. Deeks ED, "Mirogabalin : first global approval", Drugs, 79, pp.463~468 (2019)
3. Deeks ED, "Correction to : mirogabalin : first global approval", Drugs, 79, pp.469~ (2019)
4. 김경훈, "All about pain pharmacology: what pain physicians should know", The Korean Journal of Pain, 33(2), pp.108~120 (2020), 대한통증학회[DOI]
5. Hauser AS, "Trends in GPCR drug discovery: new agents, targets and indications", Nat Rev Drug Discov, 16, pp.829~842 (2017)
6. Domon Y, "Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels", J Pharmacol Exp Ther, 365, pp.573~582 (2018)
7. Dolphin AC, "Voltage-gated calcium channel α2δ subunits: an assessment of proposed novel roles", F1000Res, 7, pp.1830~ (2018)
8. Dolphin AC, "Calcium channel auxiliary α2δ and β subunits : trafficking and one step beyond", Nat Rev Neurosci, 13, pp.542~555 (2012)
9. Burnashev N, "Calcium permeability of ligand-gated channels", Cell Calcium, 24, pp.325~332 (1998)
10. Catterall WA, "Voltage-gated calcium channels", Cold Spring Harb Perspect Biol, 3, pp.a003947~ (2011)
11. D’Arco M, "The upregulation of α2δ-1 subunit modulates activity-dependent Ca2+signals in sensory neurons", J Neurosci, 35, pp.5891~5903 (2015)
12. Hoppa MB, "α2δ expression sets presynaptic calcium channel abundance and release probability", Nature, 486, pp.122~125 (2012)
13. Davies A, "Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels", Trends Pharmacol Sci, 28, pp.220~228 (2007)
14. Chincholkar M, "Analgesic mechanisms of gabapentinoids and effects in experimental pain models : a narrative review", Br J Anaesth, 120, pp.1315~1334 (2018)
15. Patel R, "Mechanisms of the gabapentinoids and α 2 δ-1 calcium channel subunit in neuropathic pain", Pharmacol Res Perspect, 4, pp.e00205~ (2016)
16. El-Awaad E, "Direct, gabapentin-insensitive interaction of a soluble form of the calcium channel subunit α2δ-1 with thrombospondin-4", Sci Rep, 9, pp.16272~ (2019)
17. Brini M, "Neuronal calcium signaling : function and dysfunction", Cell Mol Life Sci, 71, pp.2787~2814 (2014)
18. Alcántara Montero A, "Emerging therapies in clinical development and new contributions for neuropathic pain", Rev Esp Anestesiol Reanim, 66, pp.324~334 (2019)
19. Javed S, "Mirogabalin and emerging therapies for diabetic neuropathy", J Pain Res, 11, pp.1559~1566 (2018)
20. Reem Abdullah Alyoubi, "Efficacy and safety of mirogabalin treatment in patients with diabetic peripheral neuropathic pain: A systematic review and meta‐analysis of randomised controlled trials", International Journal of Clinical Practice, 75(5) (2021), Wiley[DOI]
21. Calandre EP, "Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use", Expert Rev Neurother, 16, pp.1263~1277 (2016)
22. Merante D, "The mirogabalin ALDAY phase 3 program in pain associated with fibromyalgia : the lessons learned", Curr Med Res Opin, 36, pp.661~666 (2020)
23. Burgess J, "Mirogabalin besylate in the treatment of neuropathic pain", Drugs Today(Barc), 56, pp.135~149 (2020)
24. Jansen M, "A randomized, placebo-controlled, doubleblind study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeated doses of mirogabalin in healthy Asian volunteers", Clin Pharmacol Drug Dev, 7, pp.661~669 (2018)
25. Tetsunaga T, "Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain : a retrospective study", J Orthop Surg Res, 15, pp.191~ (2020)
26. Kato J, "Longterm safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: results from an open-label extension of a multicenter randomized, double-blind, placebocontrolled trial", Medicine (Baltimore), 99, pp.e21976~ (2020)
27. Kato J, "Mirogabalin for the management of postherpetic neuralgia : a randomized, double-blind, placebo-controlled phase 3 study in Asian patients", Pain, 160, pp.1175~1185 (2019)
28. Ye X, "Cost-effectiveness of mirogabalin for the treatment of post-herpetic neuralgia in Taiwan", J Med Econ, 23, pp.529~536 (2020)
29. Baba M, "Mirogabalin for the treatment of diabetic peripheral neuropathic pain : a randomized, double-blind, placebo-controlled phase III study in Asian patients", J Diabetes Investig, 10, pp.1299~1306 (2019)
30. Vinik A, "Efficacy and safety of mirogabalin(DS-5565)for the treatment of diabetic peripheral neuropathic pain : a randomized, double-blind, placebo-and active comparator-controlled, adaptive proofof-concept phase 2 study", Diabetes Care, 37, pp.3253~3261 (2014)
31. Merante D, "DS-5565-A-U201US Phase 2 Study Investigators. Efficacy of mirogabalin (DS-5565) on patient-reported pain and sleep interference in patients with diabetic neuropathic pain: secondary outcomes of a phase II proof-of-concept study", Pain Med, 18, pp.2198~2207 (2017)
32. Baba M, "Results of mirogabalin treatment for diabetic peripheral neuropathic pain in Asian subjects : a phase 2, double-blind, randomized, placebo-controlled, study", Pain Ther, 9, pp.261~278 (2020)
33. Baba M, "Longterm safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain", J Diabetes Investig, 11, pp.693~698 (2020)
34. Hutmacher MM, "Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin(DS-5565)in patients with diabetic peripheral neuropathic pain", J Clin Pharmacol, 56, pp.67~77 (2016)
35. Arnold LM, "Efficacy and safety of mirogabalin for the treatment of fibromyalgia:results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study", Curr Med Res Opin, 35, pp.1825~1835 (2019)
36. Kim Kyongsong, "Therapeutic Effect of Mirogabalin on Peripheral Neuropathic Pain due to Lumbar Spine Disease", Asian Spine Journal, 15(3), pp.349~356 (2021), 대한척추외과학회[DOI]
37. Baba M, "Mirogabalin in Japanese patients with renal impairment and pain associated with diabetic peripheral neuropathy or post-herpetic neuralgia : a phase III, open-label, 14-week study", J Pain Res, 13, pp.1811~1821 (2020)
38. Kato M, "Pharmacokinetics and safety of a single oral dose of mirogabalin in Japanese subjects with varying degrees of renal impairment", J Clin Pharmacol, 58, pp.57~63 (2018)
39. Yin OQ, "Population pharmaco-kinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin", J Clin Pharmacol, 56, pp.203~212 (2016)
40. Duchin K, "Open-label single-dose study to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics of mirogabalin", Clin Drug Investig, 38, pp.1001~1009 (2018)
41. Dow J, "Effect of coadministration of metformin with mirogabalin : results from a phase 1, randomized, open-label, drug-drug interaction study", Int J Clin Pharmacol Ther, 56, pp.451~458 (2018)
42. Tachibana M, "Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects : a phase 1, randomized, open-label, drug-drug interaction study", Br J Clin Pharmacol, 84, pp.2317~2324 (2018)
43. Jansen M, "Pharmacokinetics, pharmacodynamics, safety, and tolerability of mirogabalin when coadministered with lorazepam, zolpidem, tramadol, or ethanol : results from drug-drug interaction studies in healthy subjects", Clin Pharmacol Drug Dev, 7, pp.597~612 (2018)
44. Brown K, "Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects : results from phase 1 studies", Pharmacol Res Perspect, 6, pp.e00418~ (2018)
45. Mendell J, "Abuse potential of mirogabalin in recreational polydrug users", Ther Adv Drug Saf, 10, pp.2042098619836032~ (2019)
46. Takahashi S, "A probable case of mirogabalin-induced neutropenia", Cureus, 12, pp.e10182~ (2020)
47. Kazuki M. Matsuda, "A case of trigeminal trophic syndrome responding to mirogabalin", European Journal of Dermatology, 30(2), pp.206~207 (2020), John Libbey Eurotext[DOI]
48. Kumar P, "Trigeminal trophic syndrome", Indian J Dermatol, 59, pp.75~76 (2014)
49. Kitano Y, "Effects of mirogabalin, a novel ligand for the α₂δ subunit of voltage-gated calcium channels, on N-type calcium channel currents of rat dorsal root ganglion culture neurons", Pharmazie, 74, pp.147~149 (2019)
50. Domon Y, "Analgesic effects of the novel α₂δ ligand mirogabalin in a rat model of spinal cord injury", Pharmazie, 73, pp.659~661 (2018)
51. Murasawa H, "Anxiolytic effects of the novel α2δ ligand mirogabalin in a rat model of chronic constriction injury, an experimental model of neuropathic pain", Psychopharmacology (Berl), 237, pp.189~197 (2020)
52. Murasawa H, "Anxiolytic-like effects of mirogabalin, a novel ligand for α2δ ligand of voltage-gated calcium channels, in rats repeatedly injected with acidic saline intramuscularly, as an experimental model of fibromyalgia", Pharmacol Rep, 72, pp.571~579 (2020)
53. Saeki K, "Analgesic effects of mirogabalin, a novel ligand for α2δsubunit of voltage-gated calcium channels, in experimental animal models of fibromyalgia", Naunyn Schmiedebergs Arch Pharmacol, 392, pp.723~728 (2019)
54. Iwai T, "Mirogabalin prevents repeated restraint stress-induced dysfunction in mice", Behav Brain Res, 383, pp.112506~ (2020)
55. Kitano Y, "Pharmacological, pharmacodynamics, and clinical profile of mirogabalin besylate (Tarlige® tablets 2.5 mg∙5 mg∙10 mg∙15mg)", Nihon Yakurigaku Zasshi, 154, pp.352~361 (2019)
56. Gong N, "Injury-induced maladaptation and dysregulation of calcium channel α2δ subunit proteins and its contribution to neuropathic pain development", Br J Pharmacol, 175, pp.2231~2243 (2018)
57. Bockbrader HN, "A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin", Clin Pharmacokinet, 49, pp.661~669 (2010)

관련 논문AI추천